In Vitro Screening for Compounds That Enhance Human L1 Mobilization

Natsuko Terasaki¹, John L. Goodier², Ling E. Cheung², Yue J. Wang², Masaki Kajikawa¹, Haig H. Kazazian Jr.², Norihiro Okada¹,3*

¹Department of Biological Science, Graduate School of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Kanagawa, Japan, ²McKusick-Nathans Institute for Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, United States of America, ³Department of Life Sciences, National Cheng Kung University, Tainan, Taiwan

Abstract

The Long interspersed element 1 (LINE1 or L1) retrotransposon constitutes 17% of the human genome. There are currently 80–100 human L1 elements that are thought to be active in any diploid human genome. These elements can mobilize into new locations of the genome, resulting in changes in genomic information. Active L1s are thus considered to be a type of endogenous mutagen, and L1 insertions can cause disease. Certain stresses, such as gamma radiation, oxidative stress, and treatment with some agents, can induce transcription and/or mobilization of retrotransposons. In this study, we used a reporter gene assay in HepG2 cells to screen compounds for the potential to enhance the transcription of human L1. We assessed 95 compounds including genotoxic agents, substances that induce cellular stress, and commercially available drugs. Treatment with 15 compounds increased the L1 promoter activity by >1.5-fold (p<0.05) after 6 or 24 hours of treatment. In particular, genotoxic agents (benzo[a]pyrene, camptothecin, cytochalasin D, merbarone, and vinblastine), PPARα agonists (bezafibrate and fenofibrate), and non-steroidal anti-inflammatory drugs (diflunisal, flufenamic acid, salicylamide, and sulindac) induced L1 promoter activity. To examine their effects on L1 retrotransposition, we developed a high-throughput real-time retrotransposition assay using a novel secreted Gaussia luciferase reporter cassette. Three compounds (etomoxir, WY-14643, and salicylamide) produced a significant enhancement in L1 retrotransposition. This is the first study to report the effects of a wide variety of compounds on L1 transcription and retrotransposition. These results suggest that certain chemical- and drug-induced stresses might have the potential to cause genomic mutations by inducing L1 mobilization. Thus, the risk of induced L1 transcription and retrotransposition should be considered during drug safety evaluation and environmental risk assessments of chemicals.

Introduction

Long interspersed element 1 (LINE1 or L1) is a non-long terminal repeat retrotransposon. L1 constitutes 17% of the human genome [1], and 80–100 human L1 elements are estimated to be potentially active in the average human [2,3]. L1s possess a 5’ untranslated region (UTR), two open reading frames (ORF1 and ORF2), and a 3’ UTR with poly(A) signal and tail [4,5]. The 5’ UTR has an internal promoter, and ORF2 encodes endonuclease [6] and reverse transcriptase [7] activities, both of which are required for autonomous retrotransposition [8]. L1s are likely to be integrated by a mechanism termed target-primed reverse transcription (TPRT) [9,10]. During TPRT, L1 endonuclease makes a nick in the first strand of the target site in the genomic DNA, and the 3’ hydroxyl at the nick is used as a primer for reverse transcription by L1-encoded reverse transcriptase. Then, second-strand cleavage occurs and the cDNA is integrated by a largely unknown mechanism. After second-strand DNA synthesis, retrotransposition is completed by the DNA repair system of the host [11]. Active L1 elements are thus considered a type of endogenous mutagen. Indeed, natural L1 insertions into genes have been discovered in many disease cases [12–14] which were caused by retrotransposition that likely occurred in the germ line. For example, progeny of active L1s have been found inserted into the genes encoding factor VIII causing hemophilia A [15], dystrophin causing muscular dystrophy [16], and pyruvate dehydrogenase X causing pyruvate dehydrogenase complex deficiency [17]. Several lines of evidence suggest that retrotransposition can occur in some somatic cells, including neuronal progenitor cells and certain cancers [18–22]. Somatic L1 insertions that occur in tumor suppressor genes may be causal for certain tumors or hasten the progression of tumorigenesis [21,23].

L1 transcription and/or mobilization is upregulated by certain types of stress: for example, genotoxic stress, which is induced by benzo[a]pyrene, UV light [24,25], gamma radiation [26], and X-ray irradiation [27]; oxidative stress, which is induced by H2O2 [28], heavy metals [29], 6-formylindolo[3,2-b]carbazole [30], and in the mouse, exercise stress [31]. Physiological stresses such as heat shock [32] can induce retrotransposons other than L1 in
various species [33]. In addition, L1 ORF1 protein is localized in cytoplasmic stress granules, which often form under stress conditions [34].

Chemical- or drug-induced retrotransposition of L1 into a functional gene in germ cells or somatic cells might cause teratogenicity or disease, including cancer. However, it is still unclear what kinds of compounds affect L1 retrotransposition, and the risk of inducing retrotransposition by compounds has not been considered during drug or chemical safety assessment.

In this study, we used a reporter gene assay in HepG2 cells to investigate compounds for their potential to enhance the transcription of human L1. We examined 95 compounds, each of which was categorized as a genotoxic agent, cellular stress agent, or drug. Of these compounds, 54 are now available commercially. Among the 95 compounds, 15 compounds (8 of which are commercially available drugs) increased the L1 promoter activity. To examine their effect on L1 retrotransposition, we designed a retrotransposition assay using a novel secreted Gaussia luciferase reporter cassette. Importantly, we found that salicylamide not only increased L1 promoter activity but also slightly enhanced L1 retrotransposition in HeLa cells. Because this drug is widely used as an anti-pyretic analgesic, the data presented here suggest a new paradigm for drug assessment.

Materials and Methods

Plasmid Constructs

pGL4.11-L1.3 5’ UTR contains the 5’ UTR of L1.3 upstream of a Firefly luciferase (FLuc) gene. The 5’ UTR was amplified by PCR using a forward primer (5’-ATGCCCTGAAGGGGGAGGAGCGCAAGATGCGG-3’) that contains the XhoI restriction site and a reverse primer (5’-GCATAGCTCTTTTGTTTTATGCTACCATTTGTGTT-3’) that contains the HindIII restriction site. The PCR product was cloned into XhoI- and HindIII-digested linearized pGL4.11 (Promega). pCEP4/L1.3mneoI400/ColE1 [35] was used as the template for the PCR. pGL4.74 (Promega) containing the herpes simplex virus thymidine kinase (HSV-TK) promoter and the Renilla luciferase (RLuc) gene was used as an internal control vector for the luciferase reporter gene assay.

99-PUR-RPS-mGLucI contains L1RP [36] with a Gaussia luciferase (GLuc) retrotransposition cassette in the 99-PUR backbone, which has a puromycin resistance gene. To construct the mGLuc retrotransposition cassette, the SV40 poly(A) signal (the construct pORF5-Fcy::Fur) [InvivoGen] was replaced with a thymidine kinase (TK) poly(A) signal. Next, an EozICRI restriction site was introduced into the GLuc gene [37] in the construct pGLuc-Basic (New England BioLabs) by QuickChange (Stratagene) mutagenesis (this introduced a D-to-E mutation at residue 39 of GLuc). The modified GLuc gene was extracted from pGLuc-Basic by PCR and swapped for the Fcy::Fur gene (between flanking NcoI and NheI sites) of pORF5-Fcy::Fur, immediately downstream of the EF-1α/eIF4 hybrid promoter. The chimeric mini-intron of the plasmid psiCHECK-2 (Promega) was isolated and cloned in the EozICRI site of GLuc in the antisense orientation. The entire reporter cassette was then extracted with flanking PacI and AsSI restriction enzyme sites, blunted, and cloned in a BsiZI site in the 3’ UTR of the active L1RP contained within the vector 99-PUR [36,38].

99-PUR-JM111-mGLucI is the JM111 mutant of 99-PUR-RPS-mGLucI. The JM111 mutant contains two missense mutations in L1RP ORF1 that abolish retrotransposition [8]. pCMV-GLuc (New England BioLabs) constitutively expresses Gaussia luciferase under a CMV promoter.

pSV40-CLuc (New England BioLabs), which contains an SV40 promoter and Cypridina luciferase (CLuc) [39], was used as an internal control vector for the high-throughput 96-well retrotransposition assay.

Ultimate ORF cDNA clones (Invitrogen) were V5-tagged on their N-termini by shuttling them from pENTR221 vector into pCDNA3.1/V5-DEST using Gateway Technology (Invitrogen) as previously described [40]. Different forms of this construct expressed the following genes: DBX39A (Invitrogen Ultimate ORF cDNA Clone number IOH3477), HNRNPK (IOH3427), HNRNPU (IOH3430), ILF2 (IOH3433), and MOV10 (IOH4005). Plasmids were purified with a Plasmid Maxi kit (Qiagen).

Cell Culture

Human hepatocellular carcinoma HepG2 cells (ATCC) and HeLa cells (ATCC) and HEK293T cells (ATCC) were grown in Dulbecco’s modified Eagle’s medium with 10% fetal bovine serum (Life Technologies, Inc.). Cell culture media was supplemented with 1 mM sodium pyruvate, 0.1 mM non-essential amino acids, 2 mM L-glutamine, and 10% fetal bovine serum (Life Technologies, Inc.). Cells were maintained at 37°C in a humidified 5% CO2 atmosphere. Cells were grown in a T75 or T225 flask to ~80% confluence and passaged using a 0.25% trypsin/0.02% EDTA solution (Sigma-Aldrich).

Test Compounds

Most of the compounds were purchased from Sigma-Aldrich, Wako Pure Chemical Industries, Ltd., or EMD Millipore. All test compounds were solubilized in dimethyl sulfoxide (DMSO) and then stored at −20°C until use. They were diluted with DMSO to different concentrations and added to the culture medium at a 1/1000 (vol/vol) dilution just before use.

Luciferase Reporter Gene Assay

HepG2 (0.33 × 10^4 cells/100 μl/well) or HeLa (0.5 × 10^4 cells/100 μl/well) cells were seeded on 96-well plates. After a 24-hour incubation, cells were cotransfected with 30 ng pGL4.11-L1.3 5’ UTR and 30 ng pGL4.74 with 0.18 μl FuGENE6 reagent (Roche) per well. At 24 hours post-transfection, cells were exposed to the various concentrations of test compounds. After 6 or 24 hours of treatment, FLuc and RLuc luminescence were measured by Multilabel Counter 1420 ARVO (PerkinElmer) using the Dual-Glo Luciferase Assay System (Promega).

Assays were performed in duplicate or quadruplicate and repeated at least twice. To analyze the effects of compounds on L1 promoter activity, the ratio of FLuc luminescence to RLuc luminescence, which was used as an internal control, was calculated, and this ratio was normalized to the ratio of the vehicle (DMSO) control. If the addition of the compound reduced promoter activity, the ratio of FLuc luminescence to RLuc luminescence was measured by Multilabel Counter 1420 ARVO (PerkinElmer) using the Dual-Glo Luciferase Assay System (Promega).

Retrotransposition Assay

Initially, Gaussia luciferase L1 reporter constructs were tested for efficacy in HEK293T cells and 6-well plates. One μg of 99-PUR-RPS-mGLucI or 99-PUR-JM111-mGLucI was cotransfected with 0.5 μg of empty vector (pCDNA3) or V5-tagged Ultimate ORF cDNA construct (four replicate wells each). At 24 hours post-transfection, 3 μl of media were replaced, and at subsequent time-points 50 μl of media was sampled from each well for time-course determination of luminescence. All readings for a single experiment were made at the same time using the
viability was determined (see below). The concentration at which the vehicle (DMSO) control was calculated. After luminescence in control CLuc luminescence was calculated. Then the ratio was cate. To evaluate the effects of compounds on L1 retrotranspo-

activity.

England BioLabs). ARVO using the BioLux Gaussia luciferase assay kit (New England BioLabs). Luminescence was measured with the Multilabel Counter 1420 ARVO. The percentage of luminescence in treated wells relative to that in control wells was used to determine cell viability. Cell viability was evaluated for four or six independent

efforts on L1 promoter activity. Among these 95 compounds, 21 genotoxic agents with various mechanisms of action, such as DNA alkylation, DNA crosslinking, and DNA topoisomerase inhibition, were evaluated (Table 1). Five genotoxic agents (benzo[a]pyrene, camptothecin, cytochalasin D, merbarone, and vinblastine) increased L1 promoter activity by >1.5-fold (p < 0.05) after exposure for 6 hours and/or 24 hours (Fig. 1). Among 9 compounds which induced >1.2-fold increase (p < 0.05) in L1 promoter activity listed in Table 1, actinomycin D, cisplatin, mitomycin C, and vinblastine are used clinically as anticancer drugs.

Benzo[a]pyrene, a DNA intercalator, increased the L1 promoter activity in a dose-dependent manner by >1.5-fold at 24 hours. This is consistent with a previous report, which showed that Benzo[a]pyrene activates mouse L1 transcription [24]. Camptothecin, a DNA topoisomerase I inhibitor, enhanced L1 promoter activity >1.5-fold only after 24 hours of treatment. Merbarone, a DNA topoisomerase II inhibitor, enhanced L1 promoter activity in a dose-dependent manner to 50 μM, and ~2-fold increases were observed at 6 and 24 hours of treatment. In contrast, etoposide, which is also a DNA topoisomerase II inhibitor, did not affect L1 promoter activity in this assay, although this compound has been reported to increase Alu retrotransposition [42]. Cytochalasin D, an actin polymerization inhibitor, and vinblastine, a microtubule assembly inhibitor, both of which inhibit reconstruction of the cytoskeleton, at their highest concentrations enhanced L1 promoter activity by 3-fold and 2-fold, respectively, after 24 hours of treatment (Fig. 1). The data for all 95 compounds including genotoxic agents are shown in Dataset S1.

Results

Effect of Genotoxic Agents on L1 Promoter Activity

We wished to determine the effects of a wide selection of environmental, genotoxic, and therapeutic compounds, including many of common human exposure, on the activity of the LINE1 retrotransposon, an insertional mutagen linked to the etiology of human disease and possibly cancers. To begin, we cloned the 5’ UTR of L1,3, one of the most active human L1s [41], upstream of a Firefly luciferase gene (FLuc). After 6 or 24 hours from the transfection of HepG2 cells with this vector, L1 promoter activity was clearly detected by FLuc expression (Fig. S1). RLuc luminescence co-expressed from vector pGL4.74 was used to normalize the transfection efficiency and to adjust for the number of cells in different wells. We used 96-well plates for high-throughput assessment.

Using the system described above, we screened 95 compounds for effects on L1 promoter activity. Among these 95 compounds, 21 genotoxic agents with various mechanisms of action, such as DNA alkylation, DNA crosslinking, and DNA topoisomerase inhibition, were evaluated (Table 1). Five genotoxic agents (benzo[a]pyrene, camptothecin, cytochalasin D, merbarone, and vinblastine) increased L1 promoter activity by >1.5-fold (p < 0.05) after exposure for 6 hours and/or 24 hours (Fig. 1). Among 9 compounds which induced >1.2-fold increase (p < 0.05) in L1 promoter activity listed in Table 1, actinomycin D, cisplatin, mitomycin C, and vinblastine are used clinically as anticancer drugs.

Benzo[a]pyrene, a DNA intercalator, increased the L1 promoter activity in a dose-dependent manner by >1.5-fold at 24 hours. This is consistent with a previous report, which showed that Benzo[a]pyrene activates mouse L1 transcription [24]. Camptothecin, a DNA topoisomerase I inhibitor, enhanced L1 promoter activity >1.5-fold only after 24 hours of treatment. Merbarone, a DNA topoisomerase II inhibitor, enhanced L1 promoter activity in a dose-dependent manner to 50 μM, and ~2-fold increases were observed at 6 and 24 hours of treatment. In contrast, etoposide, which is also a DNA topoisomerase II inhibitor, did not affect L1 promoter activity in this assay, although this compound has been reported to increase Alu retrotransposition [42]. Cytochalasin D, an actin polymerization inhibitor, and vinblastine, a microtubule assembly inhibitor, both of which inhibit reconstruction of the cytoskeleton, at their highest concentrations enhanced L1 promoter activity by 3-fold and 2-fold, respectively, after 24 hours of treatment (Fig. 1). The data for all 95 compounds including genotoxic agents are shown in Dataset S1.

Effect of Cellular Stress on L1 Promoter Activity

Next, we evaluated 27 substances that, through various mechanisms of action, induce cellular stress, including oxidative stress, mitochondrial dysfunction, and endoplasmic reticulum (ER) stress (Table 2). Four cellular stress compounds (cyclosporin A, diethyl malate, etomoxir, and exo 1) elevated L1 promoter activity by >1.5-fold (p < 0.05) after exposure for 6 and/or 24 hours (Fig. 2).

Among the cellular stresses, oxidative stress is induced by diethyl malate, iodoacetamide, and phorone, all of which increased L1 promoter activity 1.2- to 2-fold. Cyclosporin A, which induced L1 promoter activity at 24 hours, inhibits mitochondrial membrane permeabilization [43] and is a drug frequently used in organ transplants as an immunosuppressant. Etomoxir, which enhanced L1 promoter activity by >1.5-fold after 6 hours of treatment at a concentration of 500 μM, induces mitochondrial dysfunction by
inhibiting β-oxidation [44]. Exo1, which increased L1 promoter activity at 24 hours (Fig. 2), is an ER-Golgi transport inhibitor [45].

**Effect of Drugs on L1 Promoter Activity**

We used the L1 reporter gene assay to evaluate 47 drugs, 44 of which are now commercially available. These drugs have various pharmacological effects such as antilipemic, anticholesteremic, antifungal, antipyretic analgesic, antihistamine, antihypertensive, and diuretic effects (Table 3). Six drugs (bezafibrate, diflunisal, fenofibrate, flufenamic acid, salicylamide, and sulindac) increased L1 promoter activity 1.5-fold ($p < 0.05$) after exposure for 6 and/or 24 hours (Fig. 3). Among 17 compounds which increased L1 promoter activity 1.2- to 1.5-fold ($p < 0.05$), six drugs (bezafibrate, diflunisal, flufenamic acid, salicylamide, and sulindac) were especially likely to induce L1 promoter activity.

**Comparison of the Effects of Compounds on L1 Promoter Activity between HepG2 Cells and HeLa Cells**

To examine whether the chemical-enhanced L1 promoter activity is observed in HeLa cells, we performed the same experiments using HeLa cells (Fig. S2). Two test compounds, benzo[a]pyrene and merbarone, each of which elevated L1 promoter activity in HepG2 cells, were chosen for this experiment. These two compounds also enhanced the L1 promoter activity in HeLa cells in a dose-dependent manner (Fig. 4). All the data for the analysis of these two compounds in HeLa cells are shown in Dataset S2.

**Table 1. Effects of various genotoxic agents on L1 promoter activity.**

| Mechanism of action          | Compound name          | L1 promoter activity |
|------------------------------|------------------------|----------------------|
| DNA alkylator                | Busulfan               | N.S. N.S.            |
| Cyclophosphamide             | N.S.                   | –                    |
| Methyl methanesulfonate      | N.S.                   | –                    |
| DNA crosslinker              | Mitomycin C            | N.S. +               |
| DNA binder                   | Actinomycin D          | N.S. +               |
| Cisplatin                    | +                      | N.S.                 |
| Doxorubicin                  | N.S. –                 | –                    |
| DNA antimitabolite           | Cytosine arabinoside   | N.S. N.S.            |
| Fluorouracil                 | N.S. –                 | –                    |
| Methotrexate                 | N.S. N.S.              | –                    |
| 6-Thioguanine                | +                      | N.S.                 |
| DNA topoisomerase I inhibitor| Camptothecin           | N.S. +               |
| DNA topoisomerase II inhibitor| Etoposide              | N.S. N.S.            |
| Merbarone                    | + +                    | + +                  |
| DNA intercalator             | Benz[a]pyrene          | + +                  |
| Reverse transcriptase inhibitor| Aziidothymidine        | N.S. N.S.            |
| Nucleic acid analog          | Ganciclovir            | N.S. N.S.            |
| Microtubule assembly inhibitor| Colchicine             | N.S. N.S.            |
| Taxol                        | N.S. –                 | –                    |
| Vinblastine                  | N.S. +                 | + +                  |
| Actin polymerization inhibitor| Cytochalasin D         | N.S. +               |

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated with the luciferase reporter gene assay. $+$ and $++$, 1.2- to 1.5-fold increase at one or more concentrations, respectively ($p < 0.05$); $-$ and $--$, 1.2- to 1.5-fold decrease and decrease at one or more concentrations, respectively ($p < 0.05$); N.S., no significant change. The data for the L1 reporter gene assay at all test concentrations are shown in Dataset S1. doi:10.1371/journal.pone.0074629.t001

**A Novel Dual Secreted Luciferase L1 Retrotransposition Assay**

To examine whether the enhancement of L1 promoter activity might be correlated with mobilization of the L1, we conducted a cell culture retrotransposition assay. We designed a novel high-throughput assay using a secreted Gaussia luciferase retrotransposition cassette to determine retrotransposition in human cells. Gaussia luciferase (GLuc), isolated from the marine copepod *Gaussia princeps*, catalyzes the oxidation of the substrate coelenterazine, the same substrate used by Renilla luciferase [37]. As a retrotransposition reporter, Gaussia has significant advantages over other luciferases. Codon-optimized GLuc generates over 1000-fold more signal intensity than Firefly and Renilla luciferases, and is very stable in culture medium with a half-life of about 6 days [46]. Also, since most L1 insertions are severely 5′- truncated, the small size of GLuc (558 bp, compared with 936 bp for RLuc and 1653 bp for FLuc) means fewer events go undetected due to loss of reporter cassette sequence at the time of insertion. Importantly, over 90 percent of the protein is secreted so retrotransposition events can be detected by simply sampling the media without disruption of the cells. This allows for the assessment of retrotransposition at multiple time points and the ability to carry out additional experiments, such as measuring cell viability, on the...
same population of cells. Thus, many compounds can be screened simultaneously under a variety of concentrations in a 96-well format.

The secreted GLuc retrotransposition cassette consists of the GLuc gene interrupted by an antisense mini-intron, the EF-1α/eIF4g hybrid promoter (which is stronger than the CMV promoter), and the TK poly(A) signal (Fig. 5A). The GLuc retrotransposition cassette was cloned into the 3’ UTR of L1RP in the opposite orientation. L1RP is one of the most active human L1s [36] and belongs to the young Transcribed-Active (Ta) subfamily [47]. We cloned L1RP containing the GLuc retrotransposition cassette into an episomally replicating mammalian expression vector that expresses a puromycin resistance gene. The resultant plasmid was named 99-PUR-RPS-mGLucI.

All evidence indicates that Gaussia luciferase secreted into the media serves as an effective read-out of accumulated retrotransposition events. GLuc is expressed only when the intron is spliced from the chimeric L1-reporter RNA, the RNA is reverse transcribed, and its cDNA is inserted in the genome by retrotransposition. Testing initially for efficacy in 6-well plates, we cotransfected 99-PUR-RPS-mGLucI with empty vector or cDNA constructs whose protein products were previously determined to alter EGFP-reporter retrotransposition in HEK293T cell culture (Fig. 5B; [38,40]). At 24 hours post-transfection 3 mls of
media was replaced in each well, and sampling was begun. Sampling 50 ml of media from 4 replicate wells for 10 days, a strong and steady accumulation of luminescent signal was detected for 99-PUR-RPS-mGLucI but not for 99-PUR-JM111-mGLucI, a mutant L1 construct defective for retrotransposition [8]. Coexpression of 99-PUR-RPS-mGLucI with cDNAs of MOV10, DDX39, and HNRNPU reduced luminescence levels compared with empty vector alone in a manner comparable to that previously determined by the EGFP-reporter assay (performed at 5 days post-transfection). Heterogeneous nuclear ribonucleoprotein K (hnRNPK) increased retrotransposition as previously reported [40].

Kroutter et al. noted that earliest L1 retrotransposition events are detected only at 32 hours post-transfection [48]. By treating HeLa cells with reverse transcriptase inhibitor d4t, the authors were able to inhibit retrotransposition at different time points and perform a time-course analysis using the neomycin reporter assay [8]. An intronless product of 149 bp was seen in samples transfected with 99-PUR-RPS-mGLucI but not with its ORF1 mutant. By digesting isolated DNA with restriction enzymes that cut within the mini-intron prior to PCR, we were able to select against the 282-bp unspliced band amplified from plasmid DNA and increase signal from the spliced product.

While most Gaussia luciferase is secreted into the media some remains in the cells. To detect this residual luciferase, three days post-transfection we fixed cells with paraformaldehyde and performed immunofluorescence with an antibody against Gaussia luciferase (Fig. 5D). Almost no signal was detected from HEK293T cells transfected with the mutant construct 99-PUR-JM111-mGLucI, while fluorescent-positive cells transfected with 99-PUR-RPS-mGLucI were numerous.

| Mechanism of action                        | Compound name                  | L1 promoter activity |
|-------------------------------------------|--------------------------------|---------------------|
|                                           |                                | 6 h     | 24 h     |
| Oxidative stress                          | Reactive oxygen species production | Carbon tetrachloride | N.S.     | N.S.     |
|                                           |                                | 2,3-Dimethoxy-1,4-naphthoquinone | N.S.     | N.D.     |
|                                           |                                | Iodoacetamide       | +        | N.S.     |
|                                           |                                | Menadione            | N.S.     | N.D.     |
|                                           |                                | 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine | N.S.     | N.S.     |
| Glutathione depletion                     | Diethyl malate                 | + +     | N.D.     |
|                                           | Phorone                        | +        | N.S.     |
| Mitochondrial dysfunction                 | Respiratory chain inhibitor    | Antimycin A         | N.S.     | N.S.     |
|                                           |                                | 3-Nitropropionic acid | N.S.     | N.S.     |
|                                           |                                | Oligomycin          | N.S.     | −        |
|                                           |                                | Rotenone            | N.S.     | N.S.     |
|                                           |                                | Thenoyltrifluoroacetone | +        | N.S.     |
| Mitochondrial permeability transition inducer | Citrinin                    | N.S.     | +        |
| Mitochondrial membrane permeabilization   | Cyclosporin A                  | N.S.     | + +      |
| β-oxidation inhibitor                     | 1-Cyclopropanedicarboxylic acid | N.S.     | −        |
|                                           | Etomoxir                       | + +     | +        |
|                                           | 4-Pentenoic acid               | N.S.     | −        |
|                                           | Valproic acid                  | N.S.     | −        |
| Endoplasmic reticulum stress              | Calcium ionophore              | A23187              | −        | −        |
|                                           | Ionomycin                      | −        | −        |
|                                           | Tunicamycin                    | −        | −        |
| ER-Golgi transport inhibitor              | Brefeldin                      | −        | N.D.     |
|                                           | ExoI                           | +        | + +      |
| Cell proliferation                        | Growth factor                  | EGF                 | N.S.     | −        |
| Steroidogenesis activator                 | Aldosterone secretion stimulator | Angiotensin II     | N.S.     | N.S.     |
|                                           | cAMP inducer                   | Forskolin           | N.S.     | −        |

Table 2. Effects of cellular stress induced by chemicals on L1 promoter activity.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

DOI:10.1371/journal.pone.0074629.t002

end. To confirm that retrotransposition occurs in our system, we amplified by PCR genomic DNA isolated from transfected HeLa cells using primers that flank the mini-intron of mGLucI (Fig. 5C). An intronless product of 149 bp was seen in samples transfected with 99-PUR-RPS-mGLucI but not with its ORF1 mutant. By digesting isolated DNA with restriction enzymes that cut within the mini-intron prior to PCR, we were able to select against the 282-bp unspliced band amplified from plasmid DNA and increase signal from the spliced product.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the vehicle control were evaluated by luciferase reporter gene assay. For symbol definitions see Table 1.
High-throughput Testing of Compounds for Effects on Retrotransposition

The timeline for the retrotransposition assay used to query the effects of chemical compound exposure is illustrated in Figure 6A. HeLa cells were seeded on a 96-well plate and cotransfected with 99-PUR-RPS-mGLucI and pSV40-CLuc, a construct that expresses Cypridina, a secreted luciferase isolated from the marine ostracod Cypridina noctiluca [39]. CLuc reacts with Cypridina luciferin, while GLuc reacts with coelenterazine; the two bioluminescences do not cross-react and are clearly distinguished in the sample media. Furthermore, both luciferases are considerably brighter than traditional Firefly luciferase reporters.

At 24 hours post-transfection, cells were exposed to puromycin and a test compound for 2 days. The cells were treated with the test compound alone for an additional 3 days. Finally, luminescence of both GLuc and CLuc in the medium and ATP content in the cells were measured. The effect of a compound on L1 retrotransposition activity was considered valid only when cell viability was >80% of the DMSO control value.

To validate the assay system for L1 retrotransposition in 96-well plates, 99-PUR-RPS-mGLucI and 99-PUR-JM111-mGLucI vectors were individually transfected along with pSV40-CLuc into HeLa cells. GLuc and CLuc were measured 6 days post-transfection. When the wild-type plasmid was transfected, strong GLuc luminescence was detected (Fig. S4). However, retrotransposition activity, i.e. GLuc signal, was abolished by the 99-PUR-JM111-mGLucI mutant, while CLuc signal remained strong (Fig. 6B, S4).

The reverse transcriptase inhibitor azidothymidine (AZT) inhibits reverse transcription by becoming integrated into the elongating cDNA sequence. AZT inhibits L1 retrotransposition as measured with a neomycin cassette [49]. We thus tested AZT in our dual secreted luciferase retrotransposition assay. AZT treatments significantly inhibited L1 retrotransposition; <20% of control activity was observed in the presence of either 5 or 10 μM AZT (Fig. 6C). Treatment with AZT did not, however, cause cytotoxicity (Fig. 6D). Together, these data show that this high-throughput dual secreted luciferase system for the detection of L1 retrotransposition is very useful for evaluating the effects of a variety of compounds on L1 retrotransposition in HeLa cells in a 96-well format.

Analysis of the Dual Secreted Luciferase Assay for Screening the Effects of Compounds on L1 Retrotransposition

We evaluated the effects of 26 compounds on L1 retrotransposition with the dual secreted luciferase assay. Twenty one of the test compounds were chosen from among the agents that enhanced L1 promoter activity in the L1 reporter gene assay. The remaining five compounds were randomly chosen from among those that did not enhance L1 promoter activity. Among
| Pharmacology                              | Compound name                          | L1 promoter activity |
|------------------------------------------|----------------------------------------|----------------------|
|                                          |                                        | 6 h  | 24 h |
| Antilipemic PPARx agonist                | Bezafibrate                            | + +  | +   |
|                                          | Clofibrate                             | N.S. | +   |
|                                          | Fenofibrate                            | +    | +   |
|                                          | WY-14643a                              | N.S. | −   |
| Anticholesteremic HMG-CoA reductase inhibitor | Fluvastatin                            | N.S. | +   |
|                                          | Mevastatin                             | N.S. | N.S.|
|                                          | Pravastatin                            | +    | N.S.|
|                                          | Simvastatin                            | N.S. | N.S.|
| Anti-steroid drug (adrenocortical carcinoma) Steroidogenesis inhibitor | Aminoglutethimide                       | N.S. | +   |
|                                          | α,p-Dichlorodiphenyldichloroethane     | −    | N.S.|
|                                          | Metyrapone                             | +    | +   |
| Hormone drug                             | Progesterone                           | −    | −   |
|                                          | 17β-Estradiol                          | N.S. | N.S.|
|                                          | Metylestosterone                       | N.S. | −   |
|                                          | Triiodothyronin                        | N.S. | −   |
| Antifungal Ergosterol synthesis inhibitor | Ketoconazol                            | −    | −   |
|                                          | Fluconazole                            | N.S. | N.S.|
| Antipyretic analgesic COX inhibitor, nonsteroidal anti-inflammatory drug (NSAID) | Acetylsalicylic acid                    | +    | −   |
|                                          | Diclofenac                             | N.S. | −   |
|                                          | Diflunisal                             | + +  | + + |
|                                          | Flufenamic acid                        | +    | +   |
|                                          | Ibuprofen                              | N.S. | −   |
|                                          | Indometacin                            | −    | −   |
|                                          | Mefenamic acid                         | +    | N.S.|
|                                          | Salicylamide                           | + +  | + + |
|                                          | Sulindac                               | + +  | N.D.|
|                                          | Zomepirac                              | N.S. | N.S.|
| Antipyretic analgesic                    | Acetaminophen                          | N.S. | +   |
| Antihistamine H1 histamine receptor agonist | (+)-Chlorpheniramine maleate salt       | N.S. | N.S.|
|                                          | Cyproheptadine hydrochloride sesquihydrate | −    | −   |
|                                          | Epinastine hydrochloride               | −    | N.S.|
|                                          | Ketotifen fumarate salt                | −    | N.S.|
|                                          | Promethazine hydrochloride             | −    | N.D.|
| Antihistamine                            | Methapyrilene                          | −    | N.S.|
| Antitussive (S,R)-Noscapine              | −    | −   |
| Expectorant Non-narcotic central antitussive | Guaiacol glyceryl ether              | +    | +   |
|                                          | Bromhexine hydrochloride               | N.S. | N.S.|
| Hypertension Ca2+ antagonist             | Amlodipine besylate                    | N.S. | N.S.|
|                                          | Nifedipine                             | N.S. | +   |
| Angiotensin II type 1 receptor blocker   | Losartan                               | N.S. | N.S.|
|                                          | Telmisartan                            | N.S. | N.S.|
| Brain infarction Anti-platelet agent     | Spironolactone                         | N.S. | N.S.|
|                                          | Clopidogrel                            | N.S. | N.S.|
|                                          | Ticlopidine                            | N.S. | +   |
| Diuretics Loop diuretic                  | Warfarin                               | N.S. | −   |
|                                          | Furosemide                             | N.S. | −   |
|                                          | Thiazide diuretic                      | N.S. | −   |
Table 3. Cont.

The effects of treatment for 6 and 24 hours on L1 promoter activity relative to the DMSO control were evaluated by luciferase reporter gene assay.

*not commercially available. For symbol definitions see Table 1.
doi:10.1371/journal.pone.0074629.t003

the 21 compounds that elevated L1 promoter activity, etomoxir elevated L1 retrotransposition by 40.6% as compared with the control at 50 μM (p<0.0001; Fig. 7). Salicylamide, which is commonly used as an antipyretic analgesic, enhanced L1 retrotransposition activity by 23.1% at 100 μM (p<0.0001; Fig. 7). Although it did not elevate L1 promoter activity in the L1 reporter gene assay (Table 3), WY-14643, which is a PPARα agonist, increased L1 retrotransposition by 28.5% at 50 μM (p<0.05; Fig. 7). Bezafibrate, citrinin, colchicine, cyclosporin A, diflunisal, and exol significantly increased L1 retrotransposition activity to 110–120% of the control (p<0.0001; Dataset S3). All

Figure 3. Effects of commercially available drugs on L1 promoter activity in HepG2 cells. L1 promoter activity 6 and 24 hours after treatment was evaluated by the luciferase reporter gene assay. Data are represented as the average ratio (± SD) of the L1 promoter activity in the presence of the test compound relative to that in the presence of the vehicle control from two independent experiments (in quadruplicate; n = 8) for bezafibrate and fenofibrate and from two independent experiments (in duplicate; n = 4) for diflunisal, flufenamic acid, salicylamide, and sulindac. The experimental data using sulindac are shown only after 6 hours because overt cytotoxicity occurred after a 24-hour exposure (data not shown). Statistically significant differences as compared with the vehicle control for 6-hour and 24-hour treatments are indicated by * or #, respectively (#, p<0.05; ** or ##, p<0.01; *** or ###, p<0.001).
doi:10.1371/journal.pone.0074629.g003
Figure 4. Effects of benzo[a]pyrene and merbarone on L1 promoter activity in HeLa cells. L1 promoter activity 6 and 24 hours after treatment was evaluated by the luciferase reporter gene assay. Data are represented as the average ratio (± SD) of the L1 promoter activity in the presence of the test compound relative to that in the presence of the vehicle control from two independent experiments (in quadruplicate; n = 8). Statistically significant differences as compared with the vehicle control for 6-hour and 24-hour treatments are indicated by * and ***, respectively (*p<0.05; ***, p<0.001).

doi:10.1371/journal.pone.0074629.g004

Discussion

Several Compounds, Including Commercially Available Drugs, Enhance L1 Transcription and Retrotransposition

We evaluated the effects of 95 compounds on L1 transcription using a L1 reporter gene assay. Of these compounds, 15 (8 of which are commercially available drugs) significantly increased L1 promoter activity by >1.5-fold at 6 and/or 24 hours. We then assessed the effects of compounds on L1 retrotransposition. The results revealed that 3 compounds significantly increased L1 retrotransposition activity by 20–40.6% (Fig. 7). The data described above were obtained by performing experiments using controls that were carefully designed for both transcription and retrotransposition. In both cases, to normalize the actual data, an internal control with luminescence was used to estimate the efficiency of transfection and to adjust for any possible effects of compound treatment on cytotoxicity or cell growth, and hence the number of cells in different wells. In addition, in all cases the reproducibility of the data was confirmed. Especially in the case of retrotransposition, we carefully designed and performed experiments at concentrations where cytotoxicity or altered cell growth was not observed. Although the resulting ratios of the increase in transcription and retrotransposition were not large, the statistically significant effects of these compounds on transcription and retrotransposition are meaningful.

The Effects of these Compounds on Retrotransposition in vivo might be Larger than those Observed in vitro

Although our retrotransposition experiments were conducted in vitro, there is a possibility that the effects of these compounds on retrotransposition in vivo might be larger than those observed in vitro. Several factors suggest that this might be the case. First, benzo[a]pyrene, which is a DNA intercalator and an inducer of genotoxicity, induces both transcription [24] and retrotransposition [25] of L1. In our study, benzo[a]pyrene increased L1 transcription but did not increase L1 retrotransposition. We speculate that this difference may have been caused by the conditions of our retrotransposition assay. In particular, we evaluated retrotransposition in a short transient assay (i.e., 5 days), whereas the authors of the previous report used a stable cell line that could be reseeded and cultured for a long time (i.e., 14 days). Thus, we do not know what effects would be observed after long-term assessment.

A second factor that may lead to a difference in the effects seen in vitro versus those in vivo has to do with the L1. Here we used L1RP, which has very high retrotransposition activity [36]. Because of this high basal retrotransposition activity of L1RP, we may not have been able to detect enhanced retrotransposition activity, even if it was substantial. Thus, compounds that only slightly elevated L1 retrotransposition might induce retrotransposition more in vivo than would have been expected based on experiments in vitro. Moreover, it is estimated that 80 to 100 L1s remain potentially active for retrotransposition in the average diploid human genome [2,3]: exposure to a compound could activate some or all of these elements, and each to an unknown degree.

The third factor concerns the difference in conditions between in vivo and in vitro assays. In the case of the PPAR agonists, bezafibrate and fenofibrate enhanced L1 transcription and bezafibrate and WY-14643 slightly increased L1 retrotransposition. Long-term exposure of mice to WY-14643 decreases the DNA methylation in the liver of LINE1s, LINE2s, and intrasertal A particles (IAPs); the latter is an active retrotransposon in mice [50]. Furthermore, DNA methylation inhibits L1 expression, and DNA hypomethylation increases L1 retrotransposition activity [51–53]. Accordingly, PPAR agonists may activate L1 retrotransposition in addition to L1 transcription by decreasing DNA methylation. The retrotransposition assay we established in this study is a transient one that uses an episomally replicating vector: IAPs, whereas the authors of the previous report used a stable cell line that could be reseeded and cultured for a long time (i.e., 14 days). Thus, we do not know what effects would be observed after long-term assessment.

The Novel Dual Secreted Luciferase L1 Retrotransposition Assay is Useful for High-throughput Screening

Cell culture assays for retrotransposition are the most important tools for studying LINE1 elements in humans and mice. These assays report the final step of retrotransposition, the number of cells in a total population of cells that receive an insertion event. The first assay to measure retrotransposition in cells was developed...
over 25 years ago [34]. Transposition of a yeast Ty1 retrotransposon from a donor plasmid to a mutant HIS3 gene in a target plasmid resulted in a His$^+$ revertant phenotype. Spliced removal of an artificial intron engineered into the Ty1 element confirmed movement had occurred through an RNA intermediate. Subsequently, Heidmann et al. developed the neoRT reporter cassette, containing a neomycin phosphotransferase (neo) gene and an artificial intron placed between the promoter and neo coding sequence [55]. Retrotransposition events were detected by formation of neomycin (G418)-resistant colonies in cell culture.

Freeman et al. redesigned neoRT [56]. Their cassette (mneoI) included neo interrupted by an antisense mini-intron with an EF-1α/eIF4g hybrid promoter (pHFn1/peF4g) and the TK poly(A) signal (TK pA). GLuc can be expressed only when retrotransposition occurs. (B) Coexpression in HEK293T cells of selected cDNA constructs, previously determined to alter retrotransposition levels in the EGFP reporter assay (right panel; [40]), similarly affect retrotransposition in the GLuc assay (left panel). Fifty μl of media were sampled from each well (four replicate wells for each construct) at the indicated hourly time points over the course of 10 days and tested at the conclusion of the experiment (RLU: Relative Light Units). EGFP assays were performed at approximately 115 hours and results were normalized to cotransfected 99-PUR-RPS-EGFP reporter construct and empty vector (pcDNA3). Data for the earliest time-points sampled are reproduced in Fig. S3. (C) Retrotransposition in HeLa cells is confirmed by PCR using primers that flank the intron of the GLuc reporter gene. The presence of a band of 149 bp is diagnostic for intron removal. A 283-bp band is amplified from the transfected 99-PUR-RPS-mGLucI or 99-PUR-JM111-mGLucI plasmid. (D) Immunofluorescence analysis of transfected and fixed HEK293T cells showing obvious expression of GLuc from retrotransposition events formed by 99-PUR-RPS-mGLucI but not 99-PUR-JM111-mGLucI. Constitutive luciferase expression from pCMV-GLuc is also shown (right), detected by x-Gaussia antibody.

Figure 5. A novel secreted Gaussia luciferase L1 retrotransposition assay system. (A) A novel Gaussia luciferase cassette in a human L1. The mGLucI retrotransposition cassette was cloned into the 3’ UTR of L1 as the antisense orientation. The cassette contains the GLuc gene interrupted by an antisense mini-intron with an EF-1α/eIF4g hybrid promoter (pHFn1/peF4g) and the TK poly(A) signal (TK pA). GLuc can be expressed only when retrotransposition occurs. (B) Coexpression in HEK293T cells of selected cDNA constructs, previously determined to alter retrotransposition levels in the EGFP reporter assay (right panel; [40]), similarly affect retrotransposition in the GLuc assay (left panel). Fifty μl of media were sampled from each well (four replicate wells for each construct) at the indicated hourly time points over the course of 10 days and tested at the conclusion of the experiment (RLU: Relative Light Units). EGFP assays were performed at approximately 115 hours and results were normalized to cotransfected 99-PUR-RPS-EGFP reporter construct and empty vector (pcDNA3). Data for the earliest time-points sampled are reproduced in Fig. S3. (C) Retrotransposition in HeLa cells is confirmed by PCR using primers that flank the intron of the GLuc reporter gene. The presence of a band of 149 bp is diagnostic for intron removal. A 283-bp band is amplified from the transfected 99-PUR-RPS-mGLucI or 99-PUR-JM111-mGLucI plasmid. (D) Immunofluorescence analysis of transfected and fixed HEK293T cells showing obvious expression of GLuc from retrotransposition events formed by 99-PUR-RPS-mGLucI but not 99-PUR-JM111-mGLucI. Constitutive luciferase expression from pCMV-GLuc is also shown (right), detected by x-Gaussia antibody.

doi:10.1371/journal.pone.0074629.g005
Figure 6. The dual secreted luciferase L1 retrotransposition assay. (A) Timeline of dual secreted luciferase L1 retrotransposition assay. HeLa cells transfected with 99-PUR-RPS-mGLucI and pSV40-CLuc were exposed to a test compound and puromycin for 2 days. The cells were then exposed to the test compound alone for an additional 3 days. GLuc and CLuc luminescence in the medium and cellular ATP were measured with a luminometer. GLuc luminescence indicates L1 retrotransposition activity. CLuc luminescence was used for normalization as an internal control. Cell viability was evaluated by cellular ATP content. (B) Effect of JM111 (L1RP ORF1 mutant) on L1 retrotransposition activity. Either 99-PUR-RPS-mGLucI or 99-PUR-JM111-mGLucI containing two missense mutations in L1RP ORF1 and pSV40-CLuc were co-transfected. L1 retrotransposition activity is represented as normalized luminescence. ***p<0.001. (C, D) Effect of the reverse transcriptase inhibitor azidothymidine (AZT) on L1 retrotransposition activity (C) and cell viability (D). L1 retrotransposition activity and cell viability are indicated as the percentage of the vehicle control. Data in (B–D) are the mean (± SD) from four independent experiments and are expressed relative to each control. ***p<0.001.

doi:10.1371/journal.pone.0074629.g006

Figure 7. Effects of etomoxir, salicylamide, and WY-14643 on L1 retrotransposition. The effects of L1 retrotransposition activity after treatment for 5 days are shown. Data are the mean (± SD) from four independent experiments and are expressed relative to the vehicle control. **p<0.01; ***p<0.001.

doi:10.1371/journal.pone.0074629.g007
adherent cell lines, and are prone to overestimates of retrotransposition due to satellite colonies rescued from retrotransposition-positive parent colonies during the prolonged period of antibiotic selection. Osteratk et al. reduced assay time to 5 days by replacing the antibiotic resistant cassette with one expressing EGFP [38]. However, this assay requires access to a flow cytometer. Recently Xie et al. developed a “third-generation” dual-luciferase assay using the Fluc gene as reporter for L1 retrotransposition and RLuc gene for transfection normalization [64]. The approach is amenable to high-throughput assays, and data are obtainable at several days by lysing cells. 

None of the current assays permit easy study of retrotransposition kinetics and the performance of multiple assays in a single well. Different wells may be sampled sequentially to establish a time-course series [38]. More effectively, Kreutzer et al. employed a reverse-transcriptase inhibitor to halt retrotransposition at selected time points in a single experiment, permitting cells for all time-points to be harvested together at the conclusion of the experiment [48].

Cognizant of assay limitations, we designed a “fourth generation” cell culture retrotransposition assay that is easy to execute, sensitive, amenable to high-throughput analyses, and permissive for time-course sampling from a single transfected well. We constructed a novel retrotransposition cassette reporter (mGLucI) containing a modified Gaussia luciferase gene. The JM111 mutant, which exhibits almost no retrotransposition activity because of the introduction of two missense mutations in ORF1 [8,38,64], and AZT, which inhibits L1 retrotransposition [49], dramatically reduced the L1 retrotransposition activity, supporting the validity of the system. This assay system is very useful for screening many compounds at a variety of concentrations without disruption of the cells. Here we evaluated the effects of compounds on both L1 retrotransposition and cell viability using the same sample.

Genotoxic Agents and Cellular Stress Induced L1 Transcription and/or Retrotransposition as Previously Described

DNA damage induced by genotoxic stresses such as UV light [24], X-rays [27], gamma radiation [26], and some chemicals [24,65] activates L1 transcription and/or retrotransposition. In our study, some genotoxic agents increased L1 promoter activity (Fig. 1). Among the tested genotoxic agents, only colchicine, which inhibits microtubule assembly, increased L1 retrotransposition slightly, albeit significantly.

There are two possible reasons why these genotoxic agents enhance L1 retrotransposition. First, they may enhance retrotransposition through induction of DNA breaks, which would allow the integration of L1 without involving its endonuclease [66,67]. Second, genotoxic agents might induce the expression of certain transcription factors, the binding sites for which are contained in the L1 5’ UTR. Accordingly, some transcription factors, such as SRY family members [68], YY1 [69], RUNX3 [70], and p53 [71], might activate L1 transcription through their binding to the L1 5’ UTR. Indeed, it is known that genotoxic agents activate p53 protein [72,73].

Cellular stress has some effect on L1 retrotransposition, as exemplified by the increase in L1 retrotransposition that results from oxidative stress induced by H2O2 [28]. L1 ORF1 protein is localized in cytoplasmic stress granules that are formed under stress conditions [34], suggesting a possible physical connection between retrotransposition and stress. In our study, the compounds that induce mitochondrial dysfunction (such as cyclosporin A, etomoxir, and citrinin) and those that induce ER stress (such as exol) also induced L1 retrotransposition, whereas oxidative stress-inducing chemicals only increased L1 promoter activity (Table 1).

Risk Assessment of Enhanced Retrotransposition Induced by Compound Exposure should be Considered During Drug Discovery

During drug development, compounds are selected based on the assessment of their therapeutic activity and toxicity characteristics as well as pharmacokinetics (namely, absorption, distribution, metabolism, and excretion). However, the risk of retrotransposition has not yet been considered as part of drug safety assessment, even though there are several reports that chemical-induced stress activates L1 transcription and retrotransposition and that the integration of retrotransposition into genes causes disease (reviewed in [12,14,74]). In particular, salicylamide is widely used as an antipyretic analgesic, for which the peak blood concentration is 24.8 μM [75]. We observed the enhancement of retrotransposition by this drug at 50–100 μM in vitro. Although this range is higher than the peak blood concentration for salicylamide, this drug has the potential to induce retrotransposition in vivo because of long-term exposure from frequent doses. Accordingly, we believe that the data presented here provide a new paradigm for drug assessment.

Because this L1 retrotransposition assay is carried out in vitro, we should confirm these effects on L1 retrotransposition in vivo. L1 retrotransposition can be induced in skin tumors of L1 transgenic mice after exposure to 7,12-dimethylbenz[a]anthracene and 12-O-tetradecanoylphorbol-13-acetate [76]. We expect that a new in vivo assay system will be able to evaluate the enhancement of retrotransposition by compounds not only in tumors but also in germ line and somatic cells.

In conclusion, our study demonstrated that several chemicals and drugs increased L1 transcription and retrotransposition significantly and that certain chemical- and drug- induced stresses might have the potential to cause genomic mutations by inducing L1 mobilization. Because either active or passive exposure to drugs may activate retrotransposons in vivo, we propose that new assessment protocols should be undertaken during drug safety evaluation and environmental risk assessments of chemicals.

Supporting Information

Figure S1 Firefly luciferase (Fluc) and Renilla luciferase (RLuc) expression in the L1 reporter gene assay in HepG2 cells. Relative Fluc luminescence, relative RLuc luminescence, and relative normalized luciferase luminescence at 6 hours (A) and 24 hours (B) after treatment with vehicle control (DMSO) in the L1 reporter gene assay using HepG2 cells. Fluc and RLuc indicate L1 promoter activity and expression of the internal control, respectively. Data are the mean ± SD from four independent experiments. TK pro-R: pGL4.74; no pro-F: pGL4.11; L1 5’ UTR-F: pGL4.11-L1.3 5’ UTR. (TIF)

Figure S2 Fluc and RLuc expression in L1 reporter gene assay in HeLa cells. Relative Fluc luminescence, relative RLuc luminescence, and relative normalized luciferase luminescence at 6 hours (A) and 24 hours (B) after treatment with the vehicle control (DMSO) in the L1 reporter gene assay using HeLa cells. Fluc and RLuc indicate L1 promoter activity and expression of the internal control, respectively. Data are the mean ± SD from four independent experiments. TK pro-R: pGL4.74; no pro-F: pGL4.11; L1 5’ UTR-F: pGL4.11-L1.3 5’ UTR. (TIF)
L1 promoter activity 6 and 24 hours after treatment was the time-course GLuc retrotransposition assay shown in Fig. 5B. See legend for that figure.

Dataset S1 Results of L1 reporter gene assay in HepG2 cells. L1 promoter activity 6 and 24 hours after treatment was evaluated by luciferase reporter gene assay. L1 promoter activities are represented as a percentage relative to that of the vehicle control. Mean and SD from at least two independent experiments (in duplicate; n = 4 or more) are shown.

Dataset S2 Results of L1 reporter gene assay in HeLa cells. L1 promoter activity 6 and 24 hours after treatment was evaluated by the luciferase reporter gene assay. L1 promoter activities are represented as a percentage relative to that of the vehicle control. Mean and SD from two independent experiments (in quadruplicate; n = 8) are shown.

Acknowledgments
We thank Drs. John Hogness (University of Pennsylvania School of Medicine), José García Pérez (GENYO, Pfizer-University of Granada-Andalusian Government), and Priscilla Hong (New England Biolabs) for reagents and helpful advice during the development of the Gausia luciferase assay. We appreciate the assistance of the Flow Cytometry Core (SKCC, Johns Hopkins University). We also thank John Moran for generously providing the Li.3 expression vector, pCEP4/Li.3neoI400/ColEl.

Author Contributions
Conceived and designed the experiments: NT JLG MK HHK NO. Performed the experiments: NT JLG LEC YJW. Analyzed the data: NT JLG. Wrote the paper: NT JLG MK HHK NO.

References
1. Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, et al. (2001) Initial sequencing and analysis of the human genome. Nature 409: 860–921.
2. Brohka B, Schustak J, Badger RM, Lutz-Pieger S, Farley AH, et al. (2003) Hot L1s account for the bulk of retrotransposition in the human genome. Proc Natl Acad Sci U S A 100: 5280–5285.
3. Beck CR, Collier P, Marfarlane C, Malig M, Kild J, et al. (2010) LINE-1 retrotransposition activity in human genomes. Cell 141: 1159–1170.
4. Scott AF, Schmeckpeper BJ, Abdelaziz M, Comey CT, O’Hara R, et al. (1987) Origin of the human L1 elements: proposed progenitor genes deduced from a consensus DNA sequence. Genomics 1: 113–125.
5. Dombróska BA, Mathias SL, Nakahama FU, Scott AF, Kazazian HH Jr. (1990) Genomic distribution of active human transposable elements. Science 254: 1805–1808.
6. Feng Q, Moran JV, Kazazian HH Jr, Boeke JD (1996) Human L1 retrotransposon encodes a conserved endonuclease required for retrotransposition. Cell 87: 903–916.
7. Mathias SL, Scott AF, Kazazian HH Jr, Boeke JD, Gabriel A (1991) Reverse transcriptase encoded by a transposable element. Science 254: 1808–1810.
8. Moran JV, Holmes SE, Naas TP, DeBerardinis RJ, Boeke JD, et al. (1996) High frequency retrotransposition in cultured mammalian cells. Cell 87: 917–927.
9. Luan DD, Kornman MH, Jakubczak JL, Eickbush TH (1993) Reverse transcription of R2Bm RNA is primed by a nick at the chromosomal target site: a mechanism for non-LTR retrotransposition. Cell 72: 595–605.
10. Cost GJ, Feng Q, Jacquier A, Boeke JD (2002) Human L1 element target-primed reverse transcription in vitro. EMBO J 21: 3899–3908.
11. Suzuki J, Yamaguchi K, Kajikawa M, Ichiyangaki K, Adachi N, et al. (2009) Genetic evidence that the non-homologous end-joining repair pathway is involved in LINE retrotransposition. PLoS Genet 5: e1000661.
12. Chen JM, Sooason PD, Cooper DN, Feere C (2005) A systematic analysis of LINE-1 endonuclease-dependent retrotranspositional events causing human genetic disease. Hum Genet 117: 411–427.
13. Belancio VP, Deininger PL, Roy-Engel AM (2009) LINE-1 activity in the human germline: transposable elements and disease. Genome Med 1: 97.
14. Hancks DC, Kazazian HH (2012) Active human retrotransposons: variation and disease. Current Opinion in Genetics & Development 22: 191–203.
15. Kazazian HH Jr, Wong C, Youssoufian H, Scott AF, Phillips DG, et al. (1988) Haemophilia A involved in L1 retrotransposition. Nature 332: 164–166.
16. Holmes SE, Dombróska BA, Krebs CM, Boehm CD, Kazazian HH Jr (1994) A new retrotransposon of human L1 element from the LREf2 locus on chromosome 1q4 produces a chimeric insertion. Nat Genet 7: 143–148.
17. Mine M, Chen JM, Brivet M, Desguerre I, Marchant D, et al. (2007) A large genomic deletion in the PDHX gene caused by the retrotranspositional insertion of a full-length LINE-1 element. Hum Mutat 28: 137–142.
18. Muotri AR, Chao VT, Marchetto MC, Deng W, Moran JV, et al. (2005) Somatic mosaicism in neuronal precursor cells mediated by L1 retrotransposition. Nature 435: 903–910.
19. Belancio VP, Roy-Engel AM, Pochampally RR, Deininger P (2010) Somatic expression of LINE-1 elements in human tissues. Nucleic Acids Res 38: 3909–3922.
20. Kazazian HH Jr (2011) Mobile DNA transposition in somatic cells. BMC Biol 9: 62.
21. Lee, Iskow R, Yang L, Gokcumen O, Haseley P, et al. (2012) Landscape of Somatic Retrotransposition in Human Cancers. Science 337: 967–971.
22. Solyom S, Esing AD, Rahmann EP, Douret T, Nelson HH, et al. (2012) Extensive somatic L1 retrotransposition in colorectal tumors. Genome Res 22: 2328–2338.
23. Iskow RC, McCabe MT, Mills RE, Torreno S, Pirttia W, et al. (2010) Natural mutagenesis of human genomes by endogenous retrotransposons. Cell 141: 1253–1261.
24. Teneng J, Stibrinisk V, Ramos KS (2007) Context-specific regulation of LINE-1. Genes Cells 12: 1101–1110.
25. Stibrinskas V, Ramos KS (2006) Activation of human long interspersed nuclear element 1 retrotransposition by benzo[a]pyrene, an ubiquitous environmental carcinogen. Cancer Res 66: 2616–2620.
26. Farkash EA, Kao GD, Horman SR, Prak ET (2006) Gamma irradiation increases endonuclease-dependent L1 retrotransposition in a cultured cell assay. Nucleic Acids Res 34: 1196–1204.
27. Banaz-Yasar F, Gedik N, Karahan S, Diaz-Carballo D, Bongartz BM, et al. (2011) LINE-1 Retrotransposition Events Regulate Gene Expression After X-Ray Irradiation. DNA Cell Biol 31(9): 1458–1467.
28. Giorgi G, Marcamponio P, De R B (2011) LINE-1 retrotransposition in human neuroblastoma cells is affected by oxidative stress. Cell Tissue Res 346: 383–391.
29. Kale SP, Moore L, Deininger PL, Roy-Engel AM (2005) Heavy metals stimulate human LINE-1 retrotransposition. Int J Environ Res Public Health 2: 14–23.
30. Okudaira N, Ijima K, Koyama T, Minamoto Y, Kano S, et al. (2010) Induction of long interspersed nucleotide element-1 (L1) retrotransposition by 6-formylindolo[3,2-b]carbazole (FICZ), a tryptophan photoproduct. Proc Natl Acad Sci U S A 107: 10487–10492.
31. Muotri AR, Zhao C, Marchetto MC, Gage FH (2009) Environmental influence on L1 retrotransposons in the adult hippocampus. Hippocampus 19: 1002–1007.
32. Liu WM, Chu WM, Choulary PV, Schmid CW (1995) Cell stress and translational inhibitors transiently increase the abundance of mammalian SINE transcripts. Nucleic Acids Res 23: 1750–1763.
33. Wilkins AS (2010) The enemy within: an epigenetic role of retrotransposons in cancer initiation. Bioessays 32: 836–856.
34. Goodier JL, Zhang L, Vetter MR, Kazazian HH Jr (2007) LINE-1 ORF1 protein localizes in stress granules with other RNA-binding proteins, including
components of RNA interference. RNA-induced silencing complex. Mol Cell Biol 27: 6469–6483.

35. Gilbert N, Luz-Zompi S, Moran JV (2002) Genomic deletions created upon LINE-1 retrotransposition. Cell 110: 315–325.

36. Kimberland ML, Dvovsky Y, Pritch J, Schlau-Cohen U, Berger W, et al. (1999) Full-length human L1 insertions retain the capacity for high frequency retrotransposition in cultured cells. Hum Mol Genet 8: 1557–1560.

37. Verhaegn M, Christopoulos TK (2002) Recombinant Gausia luciferase. Overexpression, purification, and analytical application of a bioluminescent reporter for DNA hybridization. Anal Chem 74: 4378–4385.

38. Osterwalder EM, Prat ET, DeBerardinis RJ, Moran JV, Kazazian HH Jr (2000) Determination of L1 retrotransposition kinetics in cultured cells. Nucl Acids Res 28: 1418–1423.

39. Nakajima Y, Kobayashi K, Yamagishi K, Enomoto T, Ohmiya Y (2004) DNA cloning and characterization of a secreted luciferase from the luminous Japanese ostracod, Cypridina noctiluca. Biotech Biochem 68: 563–570.

40. Goodier JL, Cheung LE, Kazazian HH Jr (2013) Mapping the LINE-1 ORF1 protein interactome reveals associated inhibitors of human retrotransposition. Nucl Acids Res: In press.

41. Sussman DM, Dombrski BA, Moran JV, Kimberland ML, Naas TP, et al. (1997) Many human L1 elements are capable of retrotransposition. Nat Genet 16: 37–43.

42. Hagan CR, Sheffield RF, Rudin CM (2003) Human Alu element retrotransposition induced by genotoxic stress. Nat Genet 33: 219–220.

43. Broekmeier KM, Dempsey ME, Pfeiffer DR (1989) Cyclosporin A is a potent inhibitor of the inner membrane permeability transition in liver mitochondria. J Biol Chem 264: 7626–7630.

44. Gerondahs P, Albritton KG, Agius I (1989) Interactions of inhibitors of carnitine palmitoyltransferase I and farnesates in cultured hepatocytes. Biochem J 253: 169–173.

45. Feng Y, Yu S, Lasell TK, Jadhav AP, Macia E, et al. (2003) Exo1: a new chemical inhibitor of the exosyptic pathway. Proc Natl Acad Sci U S A 100: 6469–6474.

46. Tamnos BA, Kim DE, Fernandez JL, Weissleder R, Breakfield XO (2005) Codon-optimized Gaussia luciferase cDNA for mammalian gene expression in culture and in vivo. Mol Ther 11: 435–443.

47. Skowronski J, Fanning TG, Singer MF (1988) Unit-length LINE-1 transcripts in human teratocarcinoma cells. Mol Cell Biol 8: 1383–1397.

48. Krotzer EN, Belancio VP, Wagstaff BJ, Roy-Engel AM (2009) The RNA component of RNA interference RNA-induced silencing complex. Mol Cell 31: 4929–4940.

49. Dai L, Huang Q, Boeke JD (2011) Effect of reverse transcriptase inhibitors on LINE-1 and Ty1 reverse transcriptase activities and on LINE-1 retrotransposition. PLoS Genet 5: e1000458.

50. Pogribny IP, Tryndyak VP, Woods CG, Witt SE, Rusyn I (2007) Epigenetic alterations that trigger p53-dependent DNA damage response pathways. Mol Cell Biol 14: 1815–1823.

51. Bourhis D, Bestor TH (2004) Mec1p catastrophe and retrotransposition reactivation in male germ cells lacking Dmtt1L. Nature 431: 96–99.

52. Youder JA, Walsh CP, Bestor TH (1997) Cytosine methylation and the ecology of intragenomic parasites. Trends Genet 13: 335–340.

53. Muotri AR, Marchetto MC, Coufal NG, Ofner R, Yeo G, et al. (2010) L1 retrotransposition in neurons is modulated by Mc2p2. Nature 461: 443–446.

54. Boeke JD, Garfinkel DJ, Styles CA, Fink GR (1985) Ty elements transpose through an RNA intermediate. Cell 40: 491–500.

55. Heidmann T, Heidmann O, Nicolas JF (1988) An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci U S A 85: 2219–2223.

56. Freeman JD, Goodchild NL, Mager DL (1994) A modified indicator gene for selection of retrotransposition events in mammalian cells. Biotechniques 17: 46–49, 52.

57. Broshu B, Meischl C, Osterstag E, de Boer M, Zhang Y, et al. (2002) Evidence consistent with human L1 retrotransposition in maternal meiosis I. Am J Hum Genet 71: 327–336.

58. Solyom S, Esing AD, Hancks DC, Takeshima Y, Awano H, et al. (2012) Pathogenic orphan transduction created by a nonreference LINE-1 retrotransposon. Hum Mutat 33: 369–371.

59. Han JS, Boeke JD (2004) A highly active synthetic mammalian retrotransposon. Nature 429: 314–318.

60. An W, Han JS, Wheeler SJ, Davis CS, Coombes CE, et al. (2006) Active retrotransposition by a synthetic L1 element in mice. Proc Natl Acad Sci U S A 103: 18662–18667.

61. An W, Dai L, Niewiadomska AM, Yetyl A, D’Ommen KA, et al. (2011) Characterization of a synthetic human LINE-1 retrotransposon ORFeus-Hs. Mol Biotechnol 2: 2.

62. Wallace NA, Belancio VP, Faber Z, Deininger P (2010) Feedback inhibition of L1 and alu retrotransposition through altered double strand break repair kinetics. Mol DNA 1: 22.

63. Rangwala SH, Kazazian HH Jr (2009) The L1 retrotransposition assay: a retrospective and toolkit. Methods 49: 219–226.

64. Xie Y, Rosser JM, Thompson TL, Boeke JD, An W (2011) Characterization of L1 retrotransposition with high-throughput dual-luciferase assays. Nucleic Acids Res 39: e16.

65. Farkash EA, Lanning Prat ET (2006) DNA damage and L1 retrotransposition. J Biomed Biotechnol 2006: 37285.

66. Morriss TA, Garcia-Perez JM, Stamato TD, Taccioli GE, Sekiguchi J, et al. (2007) Endonuclease-independent LINE-1 retrotransposition at mammalian telomeres. Nature 446: 208–212.

67. Morriss TA, Gilbert N, Myers JS, Vincent BJ, Stamato TD, et al. (2002) DNA repair mediated by endonuclease-independent LINE-1 retrotransposition. Nat Genet 31: 159–163.

68. Tchenio T, Casella JF, Heidmann T (2000) Members of the SRY family regulate L1 and alu retrotransposition. Hum Mol Genet 9: 1761–1769.

69. Tchenio T, Casella JF, Bevak Z, Deininger P (2010) Feedback inhibition of the endonuclease-independent LINE-1 transposable element. Hum Mol Genet 2: 1697–1702.

70. Yang N, Zhang L, Zhang Y, Kazazian HH Jr (2003) A critical role for RUNX3 in human L1 transcription and retrotransposition. Nature 429: 314–318.

71. Wanstall CK, Ewing AD, Hancks DC, Takeshima Y, Awano H, et al. (2012) Pathogenic orphan transduction created by a nonreference LINE-1 retrotransposon. Hum Mutat 33: 369–371.

72. Heidmann T, Heidmann O, Nicolas JF (1988) An indicator gene to demonstrate intracellular transposition of defective retroviruses. Proc Natl Acad Sci U S A 85: 2219–2223.